Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET
Company Participants
Lina Li - Senior Director of Investor Relations and Corporate Communications
John Leonard - President & Chief Executive Officer
David Lebwohl - Chief Medical Officer
Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer
Ed Dulac - Executive Vice President & Chief Financial Officer
Conference Call Participants
Rick Bienkowski - Cantor Fitzgerald
Yanan Zhu - Wells Fargo Securities
Joseph Thome - TD Cowen
Maury Raycroft - Jefferies
Dae Gon Ha - Stifel
Jay Olson - Oppenheimer
Silvan Tuerkcan - Citizens JMP
William Pickering - Bernstein
Operator
Good morning and welcome to Intellia Therapeutics’ Third Quarter 2024 Financial Results Conference Call. My name is Drew and I will be your conference operator today. Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. As a reminder, all participants are currently in listen-only mode. [Operator Instructions]
I will now turn the conference over to Lina Li, Senior Director of Investor Relations and Corporate Communications at Intellia. Please proceed.
Lina Li
Thank you, operator and good morning, everyone. Welcome to Intellia Therapeutics third quarter 2024 earnings call. Earlier this morning, Intellia issued a press release outlining the company's progress this quarter, as well as topics for discussion on today's call. This release can be found on the Investors and Media section of Intellia's website at intelliatx.com. This call is being broadcast live and a replay will be archived on the company's website.
At this time, I'd like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law.
Joining me from Intellia are John Leonard, Chief Executive Officer; David Lebwohl, Chief Medical Officer; Laura Sepp-Lorenzino, Chief Scientific Officer; and Ed Dulac, Chief Financial Officer. John will begin with recent business highlights, David will provide updates on our clinical pipeline progress, Laura will then provide R&D updates, and Ed will review our financials before we open the call for questions.